VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
VERACYTE, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$43.80+0.68 (+1.58%)
Close on Oct 19, 2026
- Market cap
- $3.59B
- P/E (TTM)
- 31.3
- Dividend yield
- –
VERACYTE, INC. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Testing revenue | $493.15M | $418.96M | $326.54M | $250.54M | $188.18M | $101.97M | $107.36M | $91.06M | $71.95M | 95.4% | +17.7% |
| Product revenue | $14.33M | $13.65M | $15.59M | $12.63M | $11.46M | $9.85M | $923.00K | $0 | $0 | 2.8% | +5.0% |
| Biopharmaceutical and other revenue | $9.66M | $13.15M | $18.92M | $33.36M | $19.87M | $5.67M | $12.09M | – | – | 1.9% | -26.5% |
| Biopharmaceutical revenue | $6.54M | $7.15M | $13.87M | $26.34M | $12.61M | $5.67M | – | – | – | 1.3% | -8.6% |
| Other Testing Revenue | $6.20M | $11.80M | $7.80M | $3.10M | $1.10M | – | – | – | – | 1.2% | -47.5% |
| Contract manufacturing and testing | $3.13M | $6.00M | $5.05M | $7.02M | $3.26M | $0 | – | – | – | 0.6% | -47.9% |
| Biopharmaceutical | – | – | – | – | – | $5.67M | $8.09M | $950.00K | $0 | – | – |
| Collaboration | – | – | – | – | – | $0 | $4.00M | $0 | $0 | – | – |
| Provision of data | – | – | – | – | $1.88M | $1.55M | $7.09M | – | – | – | – |
| Contract testing | – | – | – | – | $383.00K | $0 | $0 | – | – | – | – |
| Development services | – | – | – | – | $10.39M | $2.12M | $1.00M | – | – | – | – |
| Development rights | – | – | – | – | $0 | $1.00M | $0 | – | – | – | – |
| Contract manufacturing | – | – | – | – | $2.87M | $0 | $0 | – | – | – | – |
| Collaboration milestones | – | – | $0 | $0 | $4.00M | $0 | $4.00M | – | – | – | – |
| Milestones | – | – | – | – | $350.00K | $1.00M | $0 | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $496.60M | $423.54M | $334.53M | $262.92M | $200.98M | $109.61M | $119.15M | $91.77M | – | 96.0% | +17.3% |
| International | $20.55M | $22.23M | $26.53M | $33.61M | $18.53M | $7.87M | $1.22M | $235.00K | – | 4.0% | -7.6% |
From the segment and revenue-disaggregation notes of Veracyte's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.